Trial of Prasinezumab in Early-Stage Parkinson’s Disease

Prasinezumab is a monoclonal antibody to α-synuclein, a protein involved in the pathogenesis of Parkinson’s disease. In a placebo-controlled trial, prasinezumab did not slow the progression of disease over a period of 52 weeks.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 387; no. 5; pp. 421 - 432
Main Authors Pagano, Gennaro, Taylor, Kirsten I., Anzures-Cabrera, Judith, Marchesi, Maddalena, Simuni, Tanya, Marek, Kenneth, Postuma, Ronald B., Pavese, Nicola, Stocchi, Fabrizio, Azulay, Jean-Philippe, Mollenhauer, Brit, López-Manzanares, Lydia, Russell, David S., Boyd, James T., Nicholas, Anthony P., Luquin, María R., Hauser, Robert A., Gasser, Thomas, Poewe, Werner, Ricci, Benedicte, Boulay, Anne, Vogt, Annamarie, Boess, Frank G., Dukart, Juergen, D’Urso, Giulia, Finch, Rebecca, Zanigni, Stefano, Monnet, Annabelle, Pross, Nathalie, Hahn, Andrea, Svoboda, Hanno, Britschgi, Markus, Lipsmeier, Florian, Volkova-Volkmar, Ekaterina, Lindemann, Michael, Dziadek, Sebastian, Holiga, Štefan, Rukina, Daria, Kustermann, Thomas, Kerchner, Geoffrey A., Fontoura, Paulo, Umbricht, Daniel, Doody, Rachelle, Nikolcheva, Tania, Bonni, Azad
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 04.08.2022
Subjects
Activities of daily living
Aging
Aging General
alpha-Synuclein - antagonists & inhibitors
Antibodies, Monoclonal, Humanized - therapeutic use
Antiparkinson Agents - therapeutic use
Clinical outcomes
Computed tomography
Dopamine
Dopamine Plasma Membrane Transport Proteins - therapeutic use
Dopamine transporter
Double-Blind Method
Geriatrics
Humans
Intravenous administration
Monoclonal antibodies
Movement disorders
Neurodegenerative diseases
Neurology
Neurosurgery
Parkinson Disease
Parkinson Disease - drug therapy
Parkinson's disease
Pathogenesis
Placebos
Putamen
Single photon emission computed tomography
Synuclein
Treatment Outcome
Online AccessGet full text

Cover

More Information
Summary:Prasinezumab is a monoclonal antibody to α-synuclein, a protein involved in the pathogenesis of Parkinson’s disease. In a placebo-controlled trial, prasinezumab did not slow the progression of disease over a period of 52 weeks.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2202867